• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Certara establishes Phoenix PK/PD Centers of Excellence in China and Japan

Certara establishes Phoenix PK/PD Centers of Excellence in China and Japan

October 13, 2016
CenterWatch Staff

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced that Peking Union Medical College (PUMC) Hospital in Beijing, China, and Keio University in Tokyo, Japan have become Phoenix Centers of Excellence.

Phoenix is the most advanced, intuitive, and widely-used software for pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) modeling and simulation. Phoenix is used by 6,000 researchers at 1,500 biopharmaceutical companies and 200 academic institutions in 60 countries. Phoenix is also employed by many global regulatory agencies including the FDA, the Japanese Pharmaceuticals and Medical Devices Agency and China Food and Drug Administration. 

“As regulators and sponsors recognize the growing importance of model-based drug development (MBDD), Certara has committed to educating the next generation of experts in this field, on a global basis,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “We are achieving that goal by partnering with eminent scientists at designated academic centers of excellence around the world and providing them with access to our Phoenix software—which is the gold standard in PK/PD—for teaching and research.”

The Phoenix Centers of Excellence routinely publish their work so that other researchers can benefit from their progress. They also serve as an informal scientific advisory group.

At PUMC Hospital, Professor Pei Hu, M.D., professor and director of its Clinical Pharmacology Research Center, will use Certara’s modeling and simulation technology for first-in-human, point-of-care, and late-phase clinical trials. MBDD strategy has been routinely applied in her unit to support Chinese new moiety entity development.

Founded by the Rockefeller Foundation in 1921, PUMC Hospital conducts clinical research into severe, rare and complicated diseases. It has 4,000 employees and is affiliated with both PUMC and the Chinese Academy of Medical Sciences. For the past six years, PUMC Hospital has been named the Number 1 hospital in the List of the Best Chinese Hospitals published by FuDan University, the most famous ranking list in China. 

Certara also has ongoing collaborations with pharmacometrics leaders in Japan. Considered to be Japan’s leader in PK/PD, Professor Yusuke Tanigawara, PhD, is professor of Clinical Pharmacokinetics and Pharmacodynamics at Keio University School of Medicine. Keio University is the oldest institute of higher education in Japan.

Certara’s other Phoenix Centers of Excellence are located at the University of Auckland School of Medicine; the State University of New York Buffalo School of Pharmacy and Pharmaceutical Sciences; the University of Minnesota School of Pharmacy; the University of North Carolina at Chapel Hill Eshelman School of Pharmacy; the University of Maryland School of Pharmacy; and the Kansas State University College of Veterinary Medicine.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing